Psoriatic arthritis is a chronic inflammatory arthropathy associated with cutaneous psoriasis.
It is a progressive disease with asymmetric joint distribution pattern and rheumatoid factor is negative.
It can develop at any time including childhood but most often occurs between 30-50 years old.
Symptoms may range from mild to very severe.
Analysis of pooled data from three phase III trials (SPIRIT-P1, -P2 and -P3) reveals that ixekizumab (IXE), a high affinity monoclonal antibody that selectively targets interleukin-17A, is a safe treatment for patients with active psoriatic arthritis (PsA), according to a study presented at the Annual European Congress of Rheumatology by the European League Against Rheumatism (EULAR 2018).
Use of apremilast monotherapy in the treatment of disease-modifying antirheumatic drugs (DMARDs)-naïve psoriatic arthritis patients is well-tolerated and helps improve signs/symptoms over 52 weeks, according to the results of the PALACE 4 trial.
Treatment with subcutaneous secukinumab leads to significant inhibition of radiographic progression and improvement of clinical signs and symptoms in patients with psoriatic arthritis, according to the results of the FUTURE 5 study.
Initial response to therapy plays a predictive role in psoriatic arthritis, such that disease activity levels 3 months after treatment initiation may be used to evaluate the potential for achieving therapeutic targets at later time points, as reported in a recent study.
There appear to be several patients with psoriasis and psoriatic arthritis (PsA) who are underdiagnosed and undertreated for hypertension and dyslipidaemia in actual situations, a recent study has found.
There appears to be a significant proportion of patients with psoriatic arthritis (PsA) in Hong Kong who have asymptomatic hyperuricaemia, which is closely associated with body mass index but not with severity of skin disease, joint involvement or renal function, according to a study.
Rheumatic diseases, particularly rheumatoid arthritis, Sjögren's syndrome, systemic lupus erythematosus, psoriatic arthritis, and osteoarthritis, appear to pose an increased risk of dementia, a study has reported.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.